These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21470018)

  • 1. Eplerenone in mild heart failure.
    Tomaschitz A; Pilz S; März W
    N Engl J Med; 2011 Apr; 364(14):1371; author reply 1372. PubMed ID: 21470018
    [No Abstract]   [Full Text] [Related]  

  • 2. Eplerenone in mild heart failure.
    Gus M; Fuchs FD
    N Engl J Med; 2011 Apr; 364(14):1370-1; author reply 1372. PubMed ID: 21470019
    [No Abstract]   [Full Text] [Related]  

  • 3. Eplerenone in mild heart failure.
    Dastidar AG
    N Engl J Med; 2011 Apr; 364(14):1371-2; author reply 1372. PubMed ID: 21470017
    [No Abstract]   [Full Text] [Related]  

  • 4. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eplerenone, an aldosterone antagonist, reduces hospitalization and death in heart failure patients with NYHA class II and an ejection fraction of less than 30%.
    Birocchi S; Cernuschi GC;
    Intern Emerg Med; 2011 Oct; 6(5):453-4. PubMed ID: 21769601
    [No Abstract]   [Full Text] [Related]  

  • 6. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
    Karagiannis A; Athyros VG; Mikhailidis DP
    Clin Cardiol; 2009 Apr; 32(4):230. PubMed ID: 19353701
    [No Abstract]   [Full Text] [Related]  

  • 8. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
    Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167
    [No Abstract]   [Full Text] [Related]  

  • 9. Aldosterone antagonists--last man standing?
    Armstrong PW
    N Engl J Med; 2011 Jan; 364(1):79-80. PubMed ID: 21073364
    [No Abstract]   [Full Text] [Related]  

  • 10. Aldosterone receptor blockade: a therapy resurrected.
    Sica DA
    Heart Dis; 2003; 5(2):85-8. PubMed ID: 12713674
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of aldosterone receptor blockade in the management of cardiovascular disease.
    Liew D; Krum H
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1468-73. PubMed ID: 12431020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone in mild heart failure.
    Pascual-Figal DA; Sanchez-Mas J; Januzzi JL
    N Engl J Med; 2011 Apr; 364(14):1370; author reply 1372. PubMed ID: 21470020
    [No Abstract]   [Full Text] [Related]  

  • 13. The risks and benefits of aldosterone antagonists.
    Sica DA
    Curr Heart Fail Rep; 2005 Aug; 2(2):65-71. PubMed ID: 16036053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.
    Funder JW
    Am Heart J; 2002 Nov; 144(5 Suppl):S8-11. PubMed ID: 12422135
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of aldosterone and aldosterone-receptor antagonists in heart failure.
    Khan NU; Movahed A
    Rev Cardiovasc Med; 2004; 5(2):71-81. PubMed ID: 15184841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aldosterone antagonist therapy for chronic heart failure].
    Yamamoto T; Yano M
    Nihon Naika Gakkai Zasshi; 2005 Feb; 94(2):262-9. PubMed ID: 15768590
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of aldosterone blockade in managing heart failure: new and emerging treatment options. Introduction.
    Aforismo JF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S2-3. PubMed ID: 15160832
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of aldosterone receptor antagonists in the management of heart failure: an update.
    Nagarajan V; Chamsi-Pasha M; Tang WH
    Cleve Clin J Med; 2012 Sep; 79(9):631-9. PubMed ID: 22949344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
    Kolloch R; Offers E
    MMW Fortschr Med; 2003 Nov; 145(47):42-4, 47. PubMed ID: 14725033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
    Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F
    Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.